RENAL CELL CARCINOMA (RCC) IN YOUNG ADULTS: A CASE REPORT AND LITERATURE REVIEW

Received 2023-09-20; Accepted 2023-12-06; Published 2024-08-01

Authors

  • Doreen Kher Lee Kiu Department of Pharmacy, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia.
  • Yew Rong Kong Department of Pharmacy, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia.
  • Yueh Ni Lim Department of Radiotherapy, Oncology & Palliative Care, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia.
  • Pei Jye Voon Department of Radiotherapy, Oncology & Palliative Care, Hospital Umum Sarawak, Kuching, Sarawak, Malaysia.

DOI:

https://doi.org/10.22452/jummec.vol27no2.3

Keywords:

Pediatric renal cell carcinoma, anti-VEGF use in pediatric population, immune checkpoint inhibitors in pediatric population, precision medicine, personalized medicine

Abstract

Pediatric renal cell carcinoma (RCC) is a rare disease entity and found to show significant differences from adult RCC in terms of epidemiological and histological subtypes. Treatment strategies for paediatric RCC were mainly adopted from adult RCC as there’s no internationally recognized standard treatment guideline to date. Data on clinical outcomes are scarce. We hereby report a case of a 14-year-old female diagnosed with advanced clear cell RCC treated with pazopanib with overall survival of 10 months. There are several case reports and case series supporting the use of anti-VEGF in adolescent RCC though not in clear cell RCC. None has incorporated immune checkpoint inhibitors in adolescent RCC. Safety and efficacy in dosing strategies of anti-VEGF in adolescents is another challenge. As cancer care advances, large scale genetic data analysis leads to the emergence of precision and personalized medicine, but its utilisation in pediatric RCC is yet to be addressed.

Downloads

Download data is not yet available.

Downloads

Published

2024-08-01

Issue

Vol. 27 No. 2 (2024)

Section

Research article

License

All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.